U.S. FDA Removes 27 Ranbaxy Generic Applications As Part Of Decree
This article was originally published in PharmAsia News
The U.S. FDA removed 27 Ranbaxy Laboratories applications for since-withdrawn generics as prescribed by a consent decree with the company earlier this year.
You may also be interested in...
India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.